Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer

James, N.D., Ali, A., Pope, A. et al. (5 more authors) (2022) Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass, 3 (6). pp. 484-493. ISSN 2688-4526

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2022 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Keywords: cabazitaxel, clinical trial, docetaxel, metastatic castrate refractory prostate cancer, phase II trial
Dates:
  • Published: November 2022
  • Published (online): 18 June 2022
  • Accepted: 2 June 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Engineering & Physical Sciences (Leeds) > School of Mechanical Engineering (Leeds) > Institute of Medical and Biological Engineering (iMBE) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 30 Nov 2023 10:45
Last Modified: 30 Nov 2023 10:45
Published Version: https://bjui-journals.onlinelibrary.wiley.com/doi/...
Status: Published
Publisher: Wiley
Identification Number: 10.1002/bco2.177
Open Archives Initiative ID (OAI ID):

Export

Statistics